The Technical Analyst
Select Language :
I-Mab [IMAB]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

I-Mab Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

I-Mab is listed at the  Exchange

0.53% CNY1.880

America/New_York / 28 mar 2024 @ 15:07


FUNDAMENTALS
MarketCap: 156.02 mill
EPS: -3.74
P/E: -0.500
Earnings Date: Mar 13, 2024
SharesOutstanding: 82.99 mill
Avg Daily Volume: 0.541 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Neutral
QUARTER GROWTHS
4/212/223/224/222/232/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebitn/an/an/an/an/an/a
Asset n/an/an/an/a
Debtn/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.500 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.09x
Company: PE -0.500 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

CNY 1.719 - 2.00

( +/- 7.58%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

Forecast 1: 15:14 - CNY1.870
Forecast 2: 16:00 - CNY1.880
Forecast 3: 16:00 - CNY1.880
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price CNY1.880 (0.53% )
Volume 0.155 mill
Avg. Vol. 0.541 mill
% of Avg. Vol 28.66 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for I-Mab

Last 12 Months

Last 12 months chart data with high, low, open and close for I-Mab

RSI

Intraday RSI14 chart for I-Mab

Last 10 Buy & Sell Signals For IMAB

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sellCNY1.799N/AActive
Profile picture for
            I-Mab

IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Last 10 Buy Signals

Date Signal @
NTRSMar 28 - 15:05$88.62
DLTRMar 28 - 15:05$133.24
FSLRMar 28 - 15:04$168.29
FWONKMar 28 - 15:04$66.20
ACLSMar 28 - 15:02$111.89
SQQQMar 28 - 14:57$10.41
FTNUSDMar 28 - 14:561.810
^NYAMar 28 - 14:42PTS18 301
^SPXMar 28 - 14:425 250.40
TUSDUSDMar 28 - 14:55$0.996

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.